Pox Viral Vaccines

  • James L. Gulley
  • Philip M. Arlen
  • Jeffrey Schlom
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Vaccine strategies must be developed in which the presentation of these TAAs to the immune system results in far greater activation of T cells than is being achieved naturally in the host. One approach to create an inflammatory milieu designed to trigger a robust immune response to TAAs involves the use of recombinant viral vectors to deliver the appropriate genetic material. Though several viral vector platforms are currently being evaluated, the pox virus family of vectors possesses several properties that make these vectors extremely attractive for use in anticancer vaccines. These include: a) the capacity to integrate the entire tumor antigen gene, parts of that gene, and/or multiple genes (including genes for costimulatory molecules and cytokines), b) the ability to infect antigen-presenting cells (APCs) allowing them to process the antigens, and c) the relative low cost. The ability to incorporate multiple transgenes within one vector is unique to these large virions, and allows for potential synergy of the incorporated gene products. This chapter will provide some insight into the strengths and weaknesses of pox viral vaccines, as well as the preclinical studies and early clinical trials of pox viral vaccine strategies for cancer therapy.


Costimulatory Molecule Recombinant Vaccinia Recombinant Vaccinia Virus Modify Vaccinia Ankara Virus General Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vaccinia (smallpox) vaccine recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 40(RR14):1–10 (12/13/1991).Google Scholar
  2. 2.
    Binns MM, Smith GL. Recombinant poxviruses. Ann Arbor, MI: CRC Press, 1992.Google Scholar
  3. 3.
    Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991; 252:1662–1667.PubMedCrossRefGoogle Scholar
  4. 4.
    Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Int Med 1997; 127:635–642.PubMedGoogle Scholar
  5. 5.
    Moss B, Flexner C. Vaccinia virus expression vectors. Ann Rev Immunol 1987; 5:305–324.CrossRefGoogle Scholar
  6. 6.
    Moss B. Poxviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Virology. Philadelphia: Lippincott-Raven, 1996:2637–2671.Google Scholar
  7. 7.
    Smith GL, Moss B. Infectious poxvirus vectors have a capacity for at least 25,000 base pairs of foreign DNA. Gene 1983; 25:21–28.PubMedCrossRefGoogle Scholar
  8. 8.
    Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, De Taisne C, Hui GS, Chang SP, Church P, Hollingdale MR, Kaslow DC, Hoffman S, Guito KP, Ballou WR, SadoffJC, Paoletti E. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996; 64:3833–3844.PubMedGoogle Scholar
  9. 9.
    Grosenbach D, Hruby DE. Construction and use of recombinant vaccinia virus vectors. Methods in molecular genetics, vol. 7. San Diego: Academic, 1995.Google Scholar
  10. 10.
    Grosenbach DW, Hruby DE. Biology of vaccinia virus acylproteins. Front Biosci 1998; 3:d354–d364. URL:
  11. 11.
    McCabe BJ, Irvine KR, Nishimura MI, et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte response. Cancer Res 1995; 55:1741–1747.PubMedGoogle Scholar
  12. 12.
    Irvine KJ, Schlom J. Comparison of a CEA-recombinant vaccinia virus, purified CEA, and an antiidiotype antibody bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Res 1993; 2:79–94.Google Scholar
  13. 13.
    Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999; 59:676–683.PubMedGoogle Scholar
  14. 14.
    Bernards R, Destree A, McKenzie S, et al. Effective tumor immunotherapy directed against an oncogeneencoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987; 19:6854–6858.CrossRefGoogle Scholar
  15. 15.
    Muraro R, Wunderlich D, Thor A, Lundy J, Noguchi P, Cunningham R, Schlom J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985; 45(Pt 2):5769–5780.PubMedGoogle Scholar
  16. 16.
    Steward AM, Nixon D, Zamcheck N, Aisenberg A. Carcinoembryonic antigen in breast cancer patients: serum levels and disease nrogress. Cancer 1974: 33:1246–1252.PubMedCrossRefGoogle Scholar
  17. 17.
    Vincent RG, Chu TM. Carcinoembryonic antigen in patients with carcinoma of the lung. J Thorac Cardiovasc Surg 1973; 66:320–328.PubMedGoogle Scholar
  18. 18.
    Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Nat! Cancer Inst 1995; 87:982–990.PubMedCrossRefGoogle Scholar
  19. 19.
    McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996; 3:495–500.PubMedCrossRefGoogle Scholar
  20. 20.
    Conry RM, Allen KO, Lee S, Moore SE, Shaw DR, LoBuglio AF. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res 2000; 6:34–41.PubMedGoogle Scholar
  21. 21.
    Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5:2330–2337.PubMedGoogle Scholar
  22. 22.
    Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6:1632–1638.PubMedGoogle Scholar
  23. 23.
    Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999; 53:260–266.PubMedCrossRefGoogle Scholar
  24. 24.
    Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg S; Tsang K, Panicali D, Poole D, Schlom J, Hamilton JM. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen independent prostate cancer. Prostate 2002; 53:109–117.PubMedCrossRefGoogle Scholar
  25. 25.
    Arlen PM, Gulley J, Novik L, Hamilton JM, Bastian A, Panicali D, Palena C, Tsang KY, Schlom J, Dahut W. Arandomized phase II trial of either vaccine therapy (recombinant pox viruses expressing PSA and the B7.1 costimulatory molecule) versus hormone therapy (nilutamide) in patients with hormone refractory prostate cancer and no radiographic evidence of disease. Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, May 18–21,2002; A728.Google Scholar
  26. 26.
    Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996: 14:428–434.PubMedCrossRefGoogle Scholar
  27. 27.
    Hodge JW, McLaughlin JP, Kantor JA, et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997; 15:759–768.PubMedCrossRefGoogle Scholar
  28. 28.
    Tartaglia J, Excler J-L, El Habib R, et al. Canarypox virus-based vaccine: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998; 14: S291-S298.Google Scholar
  29. 29.
    Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci USA 1996; 93:11341–11348.PubMedCrossRefGoogle Scholar
  30. 30.
    Trevor KT, Hersh EM, Brailey J, Balloul J-M, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother 2001; 50:397–407.PubMedCrossRefGoogle Scholar
  31. 31.
    Doehn C, Jocham D. Technology evaluation: TG-1031, transgene SA. Curr Opin Mol Ther 2000; 2: 106–111.PubMedGoogle Scholar
  32. 32.
    Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, Acres B. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000; 23:570–580.PubMedCrossRefGoogle Scholar
  33. 33.
    Bei R, Kantor J, Kashmiri SV, Abrams S, Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother Emphasis Tumor Immunol 1994; 16:275–282.PubMedCrossRefGoogle Scholar
  34. 34.
    Cole DJ, Wilson MC, Baron PL, et al. Phase I study of recombinant CEA vaccinia virus vaccine with post-vaccination CEA peptide challenge. Hum Gene Ther 1996; 7:1381–1394.PubMedCrossRefGoogle Scholar
  35. 35.
    Kahn M, Sugawara H, McGowan P, et al. CD4+ T-cell clones specific for the human p97 melanomaassociated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991; 146:3235–3241.PubMedGoogle Scholar
  36. 36.
    Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigenspecific immune responses and antitumor effects. Cancer Res. 2001; 61:4497–4505.PubMedGoogle Scholar
  37. 37.
    Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964–3973.PubMedGoogle Scholar
  38. 38.
    Marshall JL, Tsang K, Arlen P, Ley L, Slack R, Toomey M, Chang P, Schlom J. Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF (GM) and IL-2 to the combination of vaccinia-CEA (V) and Alvac-CEA (A) administered as a prime and boost in patients (pts) with advanced CEA-bearing cancers (Abstract 1087). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology. San Francisco, CA, May 12–15,2001, Vol. 20, Part 1, p. 272a.Google Scholar
  39. 39.
    Schlom J. Strategies for the use of recombinant vaccines in cancer therapy. In: Innovative strategies for immune modulation of host responses. Proceedings of the 1998 National Immunology Meeting. Bodega Bay, CA, 1998, pp. 35–50.Google Scholar
  40. 40.
    Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigenpresenting cells and acts as an immunoadjuvant. Cancer Res 2001; 61:206–214.PubMedGoogle Scholar
  41. 41.
    Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23:1094–1097.PubMedGoogle Scholar
  42. 42.
    Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, Shipley T, Fuller J, Hanke T, Sette, A, Altman JD, Moss B, McMichael AJ, Watkins DI. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/ modified vaccinia virus Ankara boost regimen. J Immunol 2000; 164:4968–4978.PubMedGoogle Scholar
  43. 43.
    Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus ME, Prince AM. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis 2000; 182:18–27.PubMedCrossRefGoogle Scholar
  44. 44.
    Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Nat! Cancer Inst 1997; 89:1595–1601.PubMedCrossRefGoogle Scholar
  45. 45.
    Slack R, Ley L, Chang P, Arlen P, Tsang K, Schlom J, Marshall JL. Association between CEA-specific T cell responses (TCR) following treatment with vaccinia-CEA (V) and Alvac-CEA (A) and survival in patients (Pts) with CEA-bearing cancers (Abstract 1086). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology. San Francisco, CA, May 12–15,2001, Vol. 20, Part 1, p. 272a.Google Scholar
  46. 46.
    Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14:483–486.PubMedCrossRefGoogle Scholar
  47. 47.
    Gollob JA, Li J, Reinherz EL, Ritz J. CD2 regulates responsiveness of activated T cells to interleukin 12. J Exp Med 1995; 182:721–731.PubMedCrossRefGoogle Scholar
  48. 48.
    Gollob JA, Li J, Kawasaki H, Daley JF, Groves C, Reinherz EL, Ritz J. Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. J Immunol 1996; 157:1886–1893.PubMedGoogle Scholar
  49. 49.
    Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999; 97:159–165.PubMedCrossRefGoogle Scholar
  50. 50.
    Schlom J, Hodge JW. The diversity of T-cell costimulation in the induction of anti-tumor immunity. Immunol Rev 1999, “Vaccines and Vaccination,” pp. 73–84.CrossRefGoogle Scholar
  51. 51.
    Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999; 11:286–293.PubMedCrossRefGoogle Scholar
  52. 52.
    Lode HN, Xiang R, Pert! U, Förster E, Schoenberger SP, Gillies SD, Reisfeld RA. Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD4OL interaction. J Clin Invest 2000; 105:1623–1630.PubMedCrossRefGoogle Scholar
  53. 53.
    Bauch A, Alt FW, Crabtree GR, Snapper SB. The cytoskeleton in lymphocyte signaling. Adv Immunol 2000; 75:89–114.PubMedCrossRefGoogle Scholar
  54. 54.
    Mueller DL. T cells: a proliferation of costimulatory molecules. Curr Biol 2000; 10:R227-R230.CrossRefGoogle Scholar
  55. 55.
    Mahajan S, Gollob JA, Ritz J, Frank DA. CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. Exp Hematol 2001; 29:209–220.PubMedCrossRefGoogle Scholar
  56. 56.
    Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole-tumor-cell vaccines. Cancer Res 1999; 59:5106–5111.PubMedGoogle Scholar
  57. 57.
    Hodge JW, Abrams S, Schlom J, Kantor J. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7–1 or B7–2 costimulatory molecules. Cancer Res 1994; 54:5552–5555.PubMedGoogle Scholar
  58. 58.
    Kalus RM, Kantor JA, Gritz L, Yafal AG, Mazzara GP, Schlom J, Hodge JW. The use of combination vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999; 17:893–903.PubMedCrossRefGoogle Scholar
  59. 59.
    Akagi J, Hodge JW, McLaughlin JP, Gritz L, Panicali D, Kufe D, Schlom J, Kantor J. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother 1997; 20: 38–47.PubMedCrossRefGoogle Scholar
  60. 60.
    Honig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000; 49:504–514.CrossRefGoogle Scholar
  61. 61.
    von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7:1181–1191.Google Scholar
  62. 62.
    Uzendoski K, Kantor JA, Abrams S, Schlom J, Hodge JW. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997; 8:851–860.PubMedCrossRefGoogle Scholar
  63. 63.
    Lorenz MGO, Kantor JA, Schlom J, Hodge J. Antitumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999; 10:1095–1103.PubMedCrossRefGoogle Scholar
  64. 64.
    Lorenz MGO, Kantor JA, Schlom J, Hodge JW. Induction of antitumor immunity elicited by recombinant vaccinia virus expressing murine leukocyte function associated antigen-3 (LFA-3). Hum Gene Ther 1999; 10:623–631.PubMedCrossRefGoogle Scholar
  65. 65.
    Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992; 148:1985–1992.PubMedGoogle Scholar
  66. 66.
    Pana E, Wingren AG, Hedlund G, Sjogren HO, Kalland T, Sansom D, Dohlsten M. Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules. Scand J Immunol 1993; 38:508–514.CrossRefGoogle Scholar
  67. 67.
    Wingren AG, Parra E, Varga M, Kalland T, Sjogren HO, Hedlund G, Dohlsten M. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15:235–253.PubMedCrossRefGoogle Scholar
  68. 68.
    Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MGO, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800–5807.PubMedGoogle Scholar
  69. 69.
    Marshall J, Odogwv L, Hwang J, Fox E, Park S, Arlen PM, et al. A Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7_1/ICAM-1/LFA-3) alone, and sequentially with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA-expressing carcinomas. (Abstract No. 622.) Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3,2003.Google Scholar
  70. 70.
    Muller G, Muller A, Jonuleit H, et al. Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches. J Invest Dermatol 2000; 114:142–149.PubMedCrossRefGoogle Scholar
  71. 71.
    Rad AN, Schlom J, Hodge JW. Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Crit Rev Oncol Hematol 2001; 39:43–57.PubMedCrossRefGoogle Scholar
  72. 72.
    Ratta M, Rondelli D, Fortuna A, et al. Generation and functional characterization of human dendritic cells derived from CD34 cells mobilized into peripheral blood: comparison with bone marrow CD34+ cells. Br J Haematol 1998; 101:756–765.PubMedCrossRefGoogle Scholar
  73. 73.
    Chatterjee SK, Qin H, Manna S, Tripathi PK. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine. Anticancer Res 1999; 19:2869–2873.PubMedGoogle Scholar
  74. 74.
    Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6:409–422.PubMedCrossRefGoogle Scholar
  75. 75.
    Zaremba S, Barzaga E, Zhu M, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997; 57:4570–4577.PubMedGoogle Scholar
  76. 76.
    Clay TM, Custer MC, McKee MD, et al. Changes in the fine specificity of gp100(209–217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999; 162:1749–1755.PubMedGoogle Scholar
  77. 77.
    Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997; 3:37–44.PubMedGoogle Scholar
  78. 78.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4:321–327.PubMedCrossRefGoogle Scholar
  79. 79.
    Schlom J and Panicali D. Recombinant pox virus vaccines. In: Rosenberg SA (ed.) Principles and Practice of the Biologic Therapy of Cancer, 3rd Ed. Philadelphia: JB Lippincott Co., 2000, pp. 686–694.Google Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • James L. Gulley
  • Philip M. Arlen
  • Jeffrey Schlom

There are no affiliations available

Personalised recommendations